Supraoptimal Peptide–Major Histocompatibility  Complex Causes a Decrease in Bcl-2 Levels and  Allows Tumor Necrosis Factor α Receptor II–mediated  Apoptosis of Cytotoxic T Lymphocytes by Alexander-Miller, Martha A. et al.
 
1391
 
The Journal of Experimental Medicine • Volume 188, Number 8, October 19, 1998 1391–1399
http://www.jem.org
 
Supraoptimal Peptide–Major Histocompatibility 
Complex Causes a Decrease in Bcl-2 Levels and 
 
Allows Tumor Necrosis Factor 
 
a
 
 Receptor II–mediated 
Apoptosis of Cytotoxic T Lymphocytes
 
By Martha A. Alexander-Miller,
 
*
 
 Michael A. Derby,
 
*
 
 Apurva Sarin,
 
‡
 
 
Pierre A. Henkart,
 
‡
 
 and Jay A. Berzofsky
 
*
 
From the 
 
*
 
Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch; and the 
 
‡
 
Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, 
Bethesda, Maryland 20892
 
Summary
 
Cytotoxic T lymphocytes (CTLs) are primary mediators of viral clearance, but high viral bur-
den can result in deletion of antigen-specific CTLs. We previously reported a potential mecha-
 
nism for this deletion: tumor necrosis factor (TNF)-
 
a
 
–mediated apoptosis resulting from stim-
ulation with supraoptimal peptide–major histocompatibility complex. Here, we show that
although death is mediated by TNF-
 
a
 
 and its receptor (TNF-RII), surprisingly neither the an-
tigen dose dependence of TNF-
 
a
 
 production nor that of TNF-RII expression can account for
the dose dependence of apoptosis. Rather, a previously unrecognized effect of supraoptimal
antigen in markedly decreasing levels of the antiapoptotic protein Bcl-2 was discovered and is
likely to account for the gain in susceptibility or competence to sustain the death signal through
TNF-RII. This decrease requires a signal through the TCR, not just through TNF-RII. Al-
though death mediated by TNF-RII is not as widely studied as that mediated by TNF-RI, we
show here that it is also dependent on proteolytic cleavage by caspases and triggered by a brief
initial encounter with antigen. These results suggest that determinant density can regulate the
immune response by altering the sensitivity of CTLs to the apoptotic effects of TNF-
 
a
 
 by de-
creasing Bcl-2 levels.
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hen confronted with extremely high levels of anti-
gen, the immune system is often unable to function
optimally. Historically, such a challenge was shown to re-
sult in a state of nonresponsiveness termed high zone toler-
ance (1). More recently, in a lymphocytic choriomeningitis
virus (LCMV) model in which the infection is not cleared
and very high titers of virus are produced within cells, it has
been reported that CTLs are deleted from the periphery
(2). This phenomenon has been termed clonal exhaustion
and is thought to be due to the repetitive stimulation of
CTLs by specific antigen. During HIV infection, as in the
LCMV model, extremely high viral loads can be obtained
that correlate with a loss of HIV-specific CTLs (3–5). It has
been postulated that clonal exhaustion may also be occur-
ring in this system.
In previous studies, we selectively expanded immune
spleen cells to obtain high and low avidity CTLs with dif-
ferent efficacies in clearing viral infections (6), and showed
that the stimulation of high avidity CTLs with APCs pre-
 
senting supraoptimal densities of peptide–MHC results in
the apoptotic deletion of CTLs (7). The appearance of ap-
optotic nuclei is maximal at 40–48 h and is mediated by
TNF-
 
a
 
. Similarly, antibodies against CD3 have also been
shown to induce a TNF-
 
a
 
–mediated apoptosis of bulk
lymph node CD8
 
1
 
 T cells (8). Therefore, it is tempting to
speculate that the in vivo death that occurs when the viral
load is very high is the result of exposure to supraoptimal
peptide–MHC determinant density similar to the death ob-
served in our in vitro model.
Perhaps it is not surprising that CTLs are restricted in the
level of stimulation that will result in their activation and
proliferation. It is now well documented that CD4
 
1
 
8
 
1
 
thymocytes can be readily stimulated to mature into single
positive cells (CD4
 
1
 
8
 
2
 
 or CD4
 
2
 
8
 
1
 
) if presented with the
appropriate peptide (9, 10). However, the concentration of
the peptide used and its affinity for the MHC molecule are
critical, as too little or too much will result in death of the
immature lymphocyte. Similarly, the capacity of a mature
 
W
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T cell to tolerate only a defined range of signal strength is
likely the result of the same qualities required for appropri-
ate thymic selection.
In this report, we further investigate the mechanism by
which apoptotic death occurs as a result of stimulation with
high dose peptide. The death is mediated by TNF-RII
rather than TNF-RI, the receptor usually associated with
TNF-mediated apoptotic death (11–14). Interestingly, al-
though both TNF and its receptor were upregulated by an-
tigen stimulation, neither the threshold for production of
TNF-
 
a
 
 nor the threshold for receptor expression was
found to correlate with the susceptibility to apoptotic
death. Thus although both TNF and TNF-RII are neces-
sary for high dose induction of apoptotic death of CTL,
under usual conditions they are not sufficient. This sug-
gested that either another molecule contributing to death is
upregulated or a protective molecule is downregulated. To
pursue this, two protective molecules, Bcl-2 and Bcl-X
 
L
 
,
were examined. Bcl-2 and Bcl-X
 
L
 
 have previously been
shown to be potent inhibitors of apoptotic death induced
under a variety of conditions (15), although their role in
TNF-
 
a
 
–mediated death is unknown. We found that a pre-
viously unrecognized effect of supraoptimal antigen levels
was to decrease the level of Bcl-2 protein in CTLs and thus
to render them competent to be killed by exposure to the
TNF-
 
a
 
 they secrete. Death required a signal, not just
through TNF-RII but also through the TCR. This finding
suggests that a decrease in Bcl-2 may account for the TNF-
 
a
 
–mediated apoptotic death triggered by supraoptimal
peptide–MHC stimulation.
 
Materials and Methods
 
Mice and Antibodies.
 
BALB/c mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). P815 is a DBA/2-derived
mastocytoma. Blocking antibodies for the TNF-RI and TNF-
RII were a gift of Dr. Robert Schreiber (Washington University
School of Medicine, St. Louis, MO) or were purchased from
Genzyme (Cambridge, MA). The biotinylated anti–TNF-R anti-
bodies were purchased from HyCult Biotechnology (Uden, The
Netherlands). FITC-avidin secondary antibody, anti–TNF-
 
a
 
capture antibody, biotin conjugated anti–TNF-
 
a
 
 detection anti-
body, anti–Bcl-2, and anti–Bcl-X were obtained from PharMin-
gen (San Diego, CA) or Genzyme. Antivinculin and antiactin
were purchased from Sigma Chemical Co. (St. Louis, MO).
 
Peptides, Protein, and Inhibitors.
 
Peptides were synthesized on
an automated peptide synthesizer (no. 430A; PE Applied Biosys-
tems, Foster City, CA) using t-boc chemistry (16) and purified as
previously described (17). The I10 peptide (RGPGRAFTVI)
represents the immunodominant CTL epitope in the V3 loop of
HIV-1 IIIB gp160 in mice of the H-2
 
d
 
 haplotype (17–19). Solu-
ble recombinant D
 
d
 
 (H-2D
 
d 
 
[
 
a
 
3]) was isolated as previously
described (20) and was the generous gift of L.F. Boyd and
D.H. Margulies (NIAID, Bethesda, MD). Boc-Asp-fluoromethyl
ketone (BD-FMK)
 
1
 
 and CBZ-Phe-Ala-fluoromethyl ketone
 
(
 
b
 
ZFA-FMK) were obtained from Enzyme System Products,
(Livermore, CA).
 
Generation of CTL Lines.
 
7.5 
 
3 
 
10
 
6
 
 responding BALB/c
spleen cells from mice previously immunized with a recombinant
vaccinia virus expressing the gp160 protein from HIV-1
 
IIIB
 
 were
cocultured either with 3.5 
 
3 
 
10
 
6
 
 stimulating irradiated (3,000 rads)
BALB/c splenocytes previously pulsed with various concentra-
tions (100, 0.1, or 0.0001 
 
m
 
M) of I10 peptide or with irradiated
nonpulsed splenocytes in the presence of 1 
 
m
 
M free peptide in
24-well plates containing 2 ml/well of a 1:1 mixture of RPMI
1640 and Eagle-Hanks Amino Acid (EHAA) medium supple-
mented with L-glutamine, sodium pyruvate, nonessential amino
acids, penicillin, streptomycin, 5 
 
3 
 
10
 
2
 
5
 
 M 
 
b
 
-mercaptoethanol, 10%
FCS, and 10% T-stim (Collaborative Biomedical Products, Bed-
ford, MA). CTL lines were established from primary cultures and
were maintained by weekly restimulation of 3–5 
 
3 
 
10
 
5
 
 cells/well
in the presence of 5 
 
3 
 
10
 
6
 
 irradiated (3,000 rads) BALB/c spleen
cells pulsed with the appropriate concentration of I10 peptide.
 
Proliferation Assays.
 
CTLs were plated at 5 
 
3 
 
10
 
4
 
/well in a
96-well round-bottomed microtiter plate. Irradiated (3,000 rads)
BALB/c splenocytes previously pulsed with I10 peptide and
washed three times were added at 3 
 
3 
 
10
 
5
 
/well. Supernatant
from the final wash of stimulators pulsed with 100 
 
m
 
M I10 pep-
tide was reserved and added to wells with 0.001-
 
m
 
M-pulsed stim-
ulators at a final dilution of 1:1 to ensure that effects seen with
100-
 
m
 
M-pulsed stimulators were not due to residual free I10
peptide that might have bound to the CTLs directly. In some
cases, anti–TNF-RI or anti–TNF-RII blocking antibodies (21)
were added at 5 
 
m
 
g/well. Proliferation was measured by addition
of 1 
 
m
 
Ci [
 
3
 
H]thymidine per well at 24 and 48 h and plates were
harvested at 48 and 72 h, respectively. Results obtained at the
second harvest were qualitatively similar. Results were expressed
as the geometric mean of triplicate cultures.
 
Assay for TNF-
 
a
 
 Production.
 
CTLs were stimulated with
pulsed spleen APCs, as for proliferation assays, or with substrate-
bound soluble D
 
d
 
. To measure soluble TNF-
 
a
 
, culture superna-
tant was harvested at 24 h and assayed for TNF-
 
a
 
 by an ELISA
using capture and biotinylated detecting antibodies from Phar-
Mingen as described in their Cytokine ELISA Protocol. Surface-
bound TNF-
 
a
 
 was detected at various times after stimulation
using anti–TNF-
 
a
 
 or isotypic control FITC- or PE-conjugated
antibodies.
 
Apoptotic Death Assays.
 
To detect apoptotic nuclei, CTLs
were enriched by centrifuging lines over ficoll to remove irradi-
ated APCs. After washing, 5 
 
3 
 
10
 
4
 
 CTLs were added along with
3 
 
3 
 
10
 
5
 
 peptide-pulsed stimulators (depleted of Thy 1.2
 
1
 
 cells) in
0.2 ml of medium that contained 10% T-stim as a source of IL-2
per well of a 96-well plate in triplicate. After 40–45 h, cells were
harvested and incubated with biotin-conjugated Thy 1.2 mAb
and FcBlock followed by PE-avidin (to identify CTLs), washed,
and incubated for 30 min with 5 
 
m
 
g/ml Hoechst 33342 (Molecu-
lar Probes, Inc., Eugene, OR) at 37
 
8
 
C. Cells were then centri-
fuged and the pellet was resuspended in 20 
 
m
 
l PBS. Apoptotic
nuclei were identified by fluorescent microscopy (22). Apoptosis
was also estimated by the reduction in CTL proliferation at 24 or
48 h and the decrease in forward and side scatter detected by flow
cytometry.
 
Flow Cytometry.
 
For flow cytometric analysis, 2 
 
3 
 
10
 
5
 
 cells
were washed and resuspended in PBS containing 0.2% BSA and
0.1% sodium azide. Cells were incubated on ice with the appro-
priate antibody for 30 min and then washed. Where necessary, a
secondary reagent was then added for an additional 30 minutes
and the cells were again washed. Samples were analyzed on a
 
1
 
Abbreviations used in this paper:
 
 AICD, activation-induced cell death; BD-
FMK, Boc-Asp-fluoromethyl ketone; 
 
b
 
ZFA-FMK, CBZ-Phe-Ala-fluo-
romethyl ketone; TRAF, TNF receptor–associated factor. 
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FACScan
 
Ò
 
 (Becton Dickinson, Mountain View, CA). Back-
ground staining was assessed by use of a similarly conjugated iso-
typic control antibody or by staining with the secondary antibody
alone or by the secondary antibody after an unconjugated isotypic
control primary antibody.
 
Western Blot Analysis.
 
Immulon IV plates were coated with
soluble D
 
d
 
 protein (0.4–0.5 
 
m
 
g/well) or anti–TNF-RII antibody
(0.5 
 
m
 
g/well) in PBS for 2–3 h at 37
 
8
 
C or overnight at 4
 
8
 
C.
Wells were washed, blocked with RPMI containing 10% FCS for
1 h, and washed again. I10 peptide in RPMI plus 10% FCS at the
appropriate concentration was added to wells coated with soluble
D
 
d
 
 and allowed to bind overnight at 37
 
8
 
C. Wells were then
washed extensively. CTLs harvested 3–5 d after routine stimula-
tion were ficolled to remove APCs and added at 1.5 
 
3 
 
10
 
5
 
/well.
5 
 
3 
 
10
 
6
 
 CTLs were used per antigen concentration tested. CTLs
were cultured for 24 h, and then harvested and lysed with 0.5%
Triton X-100 containing leupeptin, aprotinin, PMSF, and io-
doacetamide. After 45 min on ice, samples were centrifuged and
the supernatant was removed and pellet discarded. Sodium deoxy-
cholate (10% final) and SDS (0.2% final) were added to the su-
pernatant. 6 
 
3 
 
10
 
5
 
 cell equivalents per sample were run on either
a 13 or a 4–12% gradient polyacrylamide gel in either Tris-gly-
cine or MES [2-(
 
N
 
-morpholino) ethane sulfonic acid] buffer sys-
tems (Novex, San Diego, CA). Separated proteins were trans-
ferred onto nitrocellulose membrane and the blots were blocked
overnight with either powdered milk/bovine albumin or Super-
Block-TBS (Pierce Chemical Co., Rockford, IL). After incuba-
tion with rabbit antiactin or antivinculin, and rabbit anti–Bcl-2 or
anti–Bcl-X
 
L
 
 for 1 h, the blots were washed, and then FITC- or
alkaline phosphatase–conjugated secondary goat anti–rabbit was
added for 1 h. After a further wash, FITC-conjugated secondary
antibody was directly quantitated with a Storm fluoroimaging
system using ImageQuant (Molecular Dynamics, Sunnyvale,
CA). Alternatively, alkaline phosphatase–conjugated secondary
was indirectly visualized photographically by reaction with a
chemiluminescent substrate.
 
Results
 
A Single Brief Exposure to High Dose Antigen Is Adequate to
Irreversibly Trigger CTL Death.
 
In a previous study from
this laboratory, we described the TNF-
 
a
 
–mediated apop-
totic death of CD8
 
1
 
 CTLs in response to high (supraopti-
mal) peptide–MHC determinant density (7). The induc-
tion of the death signal in resting and recently activated
CTLs was found to be identical, and death required 
 
z
 
40 h
in both cases. These observations of the death process in
CD8
 
1
 
 CTLs differ from those for the activation-induced
cell death (AICD) of CD4
 
1
 
 T cells (23–26). Studies of
AICD in CD4
 
1
 
 T cells suggest that antigen can induce
death only in cycling cells. Resting cells would thus require
two signals, the first to induce entry into the cell cycle and
the second to actually initiate apoptosis. To distinguish be-
tween these two mechanisms in the case of CD8
 
1
 
 T cells,
we investigated the required length of time for antigen pre-
sentation to CTLs in order to trigger apoptosis by two ap-
proaches. First, to ensure a discrete, limited exposure to
MHC–peptide, resting CTLs (11 d after stimulation) were
activated by plate-bound, recombinant soluble D
 
d
 
 mole-
cules pulsed with high dose peptide antigen (Fig. 1 A).
CTLs were removed from the antigen at various time
points and replated in wells with normal medium in the ab-
sence of specific peptide–MHC (I10/Dd). At 44 h the
CTLs were analyzed by Hoechst staining for the presence
of apoptotic nuclei. As little as 2 h of exposure to antigen
was adequate to initiate the cell death pathway in a signifi-
cant portion of the population, and maximal death was in-
duced by only 4 h exposure to supraoptimal antigen (Fig.
1 A). These data suggest that the initial exposure to high dose
(supraoptimal) antigen is sufficient for the induction of the
death signal. Second, to explore the role of continued anti-
gen exposure, resting CTLs were exposed to APCs pulsed
with either high or low doses of peptide for 6 h, and were
then moved to different conditions. APCs were removed
from the cultures by passage over an R&D T cell enrich-
ment affinity column (coated with Ig-anti-Ig to remove
surface Ig and Fc receptor-bearing cells; R&D Systems,
Inc., Minneapolis, MN), and the CTLs were replated with
fresh APCs presenting either a high or low determinant
density. FACSÒ analysis showed that the recovered CTLs
were essentially free of APCs; .98% were I-Ad negative.
Also, a control supernatant from the last wash of the APCs
was tested for its ability to induce apoptosis to show that no
free peptide was carried over to be presented by the CTLs
themselves (data not shown). CTLs that were exposed to
high-dose antigen for 6 h and then replated with APCs
bearing high or low density antigen or no antigen under-
went apoptotic death to the same extent as cells that were
continuously exposed to APCs pulsed with high dose anti-
Figure 1. The trigger for ap-
optotic death is a result of the
initial encounter with supraopti-
mal peptide–MHC determinant
density. (A) Wells of an Immu-
lon IV plate were coated with
0.5  mg of recombinant Dd,
blocked, and pulsed with 50 mM
I10 peptide. After extensive
washing, 105 resting CTLs were
added to each well. CTLs were
transferred to wells without Dd/
I10 at the times indicated and the
culture period continued. At 45 h
after initiation of the culture,
CTLs were harvested and as-
sessed for apoptotic nuclear mor-
phology by Hoechst 33342
staining. The CTLs were irre-
versibly triggered to undergo ap-
optotic death after as little as 2 h of antigen exposure. (B) Resting high
avidity CTLs were cultured for 6 h in the presence of stimulators pulsed
with a high (100 mM) or low (0.01 mM) concentration of I10 peptide.
CTLs were then recovered by passage over an R & D T cell purification
column, replated with fresh stimulators previously pulsed with various
concentrations of I10 peptide, and cultured for an additional 37 h. As
controls for the induction of apoptotic death, CTLs were continuously
cultured in the presence of stimulators pulsed with high concentrations of
peptide (positive control) or low concentrations of peptide (negative con-
trol) for 45 h. CTLs exposed to supraoptimal peptide–MHC determinant
density for only 6 h underwent apoptotic death to the same extent as
CTLs cultured in the continuous presence of APCs that presented high
density peptide–MHC, clearly demonstrating that the initial encounter
with high peptide–MHC determinant density can signal death in CTLs.1394 High Antigen Density Decreases Bcl-2 Levels In CTLs
gen (Fig. 1 B). These data demonstrate that an initial en-
counter with high (supraoptimal) antigen induces a signaling
event quite different from that induced by an encounter
with low (optimal) antigen. Furthermore, they distinguish
the apoptotic mechanisms of CD81 T cells stimulated with
supraoptimal antigen from the AICD seen in CD41 T cells.
Production of TNF-a by High Avidity CTLs Does Not Cor-
relate with Susceptibility to Apoptotic Death. What is the na-
ture of the signaling event that distinguishes high and low
dose antigen? The most ready explanation for the TNF-
a–mediated death after stimulation by APCs pulsed with
high doses of antigen was that supraoptimal stimulation was
required to induce production of TNF-a by the CTLs.
Fig. 2 shows that these CTLs did indeed produce TNF-a
when stimulated with high doses of peptide antigen that in-
duced inhibition of proliferation; however, maximal TNF-a
production also occurred at lower antigen concentrations
where maximal proliferation was observed. We have previ-
ously shown that inhibition of the proliferative response by
high dose antigen is correlated with the induction of apop-
totic death (7). Thus, the threshold for production of
TNF-a did not solely account for the death observed with
high dose antigen. Furthermore, addition of exogenous
TNF-a in the presence of stimulators pulsed with an opti-
mal (low) concentration of antigen did not induce death
(data not shown). Because TNF-a can exist in a mem-
brane-bound form as well as a soluble form, and since
membrane-bound TNF-a has been suggested as the active
form interacting with TNF-RII (27), we also asked
whether levels of surface TNF-a could be correlated with
the high dose antigen induction of apoptosis. However, we
found that, as with soluble TNF-a, surface TNF-a also
reaches a plateau at low antigen density, two logs lower
than does apoptosis, and does not increase further at high
antigen density (Fig. 3). As the concentration of antigen re-
quired for TNF-a production did not correlate with the
concentration that resulted in apoptotic death, the induc-
tion of TNF-receptor by high dose antigen was investi-
gated.
The Signal Required for Death Is Mediated by Binding of
TNF-a to the TNF-RII Receptor. Our previous studies in-
dicated that anti–TNF-a antibody could block the apop-
totic death of high avidity CTLs induced by stimulation
with a high concentration of antigen (7). It seemed likely
that this was mediated by TNF-RI, since the majority of
TNF-a–mediated apoptotic death has been shown to in-
volve signaling via the TNF-RI receptor (11–14). How-
ever, in several instances, including AICD of bulk CD81
lymph node cells stimulated with anti-CD3, TNF-RII has
been demonstrated to be the mediator of the death signal
(8). To determine which receptor was involved in the
TNF-a–mediated inhibition of proliferation and the corre-
lated apoptotic death in our system, we used blocking anti-
bodies to TNF-RI and TNF-RII. Addition of antibodies
during proliferation assays demonstrated that binding of
TNF-a to TNF-RII was required for inhibition, but that
there appeared to be no role for TNF-RI (Fig. 4).
Figure 2. The threshold of stimulation resulting in TNF-a production
does not correlate with the threshold required for apoptotic death. CTLs
were assayed concurrently for production of TNF-a and for proliferation
in response to stimulation with splenocytes pulsed with various concen-
trations of I10 peptide. Production of TNF-a was quantitated by ELISA
of culture supernatants. CTLs were stimulated by APCs pulsed with the
indicated concentration of peptide antigen. After 24 h of culture, super-
natant was collected and assayed for TNF-a. Proliferation was assessed as
the incorporation of [3H]thymidine between 24 and 48 h of culture. As
peptide concentration increased, TNF-a production rose concurrently
with the rate of proliferation until both reached maximums at similar con-
centrations of peptide. With further increases in peptide concentration,
proliferation decreased, characteristic of the high antigen induction of ap-
optosis, whereas TNF-a production remained elevated. Because TNF-a
production was maximal at antigen concentrations too low to observe ap-
optosis or inhibition of proliferation, the requirement for high dose anti-
gen to trigger apoptotic death is not the result of the stimulation threshold
for TNF-a production.
Figure 3. Surface-bound TNF-a is dependent upon antigen density
and is not correlated with apoptosis. 5 d after stimulation, high avidity
CTLs were stimulated with Thy 1.2–depleted spleen cells pulsed with
various concentrations of I10 peptide. After 24 h in culture, cells were
harvested and washed, and surface-bound TNF-a was detected by FITC-
conjugated antibody using flow cytometry, gating only Thy 1.2–positive
cells to exclude antigen presenting cells. The mean fluorescence was de-
termined for CTLs in both the viable and apoptotic gates based on for-
ward versus side scatter. Apoptosis was measured in the same samples as
the number of CTLs in the apoptotic gate taken as a percentage of the to-
tal CTLs in both viable and apoptotic gates. Surface-bound TNF-a in-
creased at optimal levels of peptide, two logs lower than peptide concen-
trations sufficient to cause apoptosis under these conditions. Similar results
were obtained in three additional experiments.1395 Alexander-Miller et al.
TNF-a Receptor Expression. Since the amount of anti-
gen required for either soluble or surface-bound TNF-a
production could not explain the regulation of apoptotic
death, it was possible that the differential susceptibility to
TNF-a after stimulation with different determinant densi-
ties was manifested in the expression of TNF-RII. Accord-
ingly, CTLs exposed to various concentrations of peptide
were analyzed by flow cytometry for the surface expression
of TNF-RII. As shown in Fig. 5, the results were similar to
those seen for TNF-a. At the high peptide concentration
that induced a decrease of proliferation, TNF-RII levels
were indeed high, but they were also high at lower (opti-
mal) concentrations of peptide. Furthermore, levels of
TNF-RII increased with a dose–response curve that mir-
rored the one for proliferation. Therefore, as was observed
for the production of TNF-a, expression of TNF-RII be-
comes maximal at too low an antigen density to account
for the susceptibility to TNF-a–mediated death at high
doses of antigen. These results suggested that if neither the
expression of TNF-a nor that of its receptor is sufficient to
account for the high antigen density-induced apoptosis
then the engagement of TCR by high antigen density must
potentiate the susceptibility of CTLs to a subsequent death
by signals through the TNF-RII receptor. This potentia-
tion could be the result of an increase in an actively apop-
totic molecule or, conversely, the decrease in a protective
molecule (such as Bcl-2 or Bcl-XL).
Regulation of Bcl-2 and Bcl-XL by Antigen Dose. There is
significant evidence that the antiapoptotic proteins Bcl-2
and Bcl-XL are important in the regulation of cell death in
T lymphocytes (15). Therefore, the expression of these two
molecules in CTLs undergoing apoptotic death was ana-
lyzed after stimulation with supraoptimal peptide–MHC.
To preclude any contribution from stimulator cells to the
analysis, immobilized recombinant H-2Dd protein pulsed
with various peptide concentrations was used to stimulate
the CTLs. High avidity CTLs were incubated for 24 h in
the presence of immobilized H-2Dd molecules pulsed with
50 mM I10 peptide, 0.005 mM I10 peptide, or no peptide.
After incubation, CTLs were harvested and the levels of
Bcl-2 and Bcl-XL extracted with Triton X-100 were ana-
lyzed by Western blot analysis. After stimulation with high
dose antigen, the level of Bcl-2 was significantly reduced
compared with cultures stimulated with optimal antigen
doses (Fig. 6). This reduction ranged from 65 to 99% de-
pending on the individual assay and method of detection.
In contrast, when Bcl-XL was analyzed by Western blots
under parallel conditions, there was little or no difference
in concentration under any conditions (data not shown).
As expected, low avidity CTLs, which do not undergo
apoptotic death after stimulation with high dose antigen,
showed no decrease in Bcl-2 or Bcl-XL with any antigen
concentration. Correspondingly, under optimal (low) dose
antigen conditions where high avidity CTLs also show no
increase in apoptosis, levels of Bcl-2 were likewise not de-
creased. Therefore, it is likely that a decrease in Bcl-2 levels
is the third process induced by high dose antigen stimula-
tion of the TCR that allows the cells to undergo TNF-medi-
ated apoptosis.
The Decrease in Bcl-2 Is Dependent upon TNF-a Signaling,
but this Signal Is Enabled Only by TCR Stimulation with High
Dose Antigen. Because the high dose antigen that causes a
decrease in Bcl-2 levels also induces production of TNF-a
and expression of TNF-RII, we asked whether TNF-a/
TNF-RII signaling was necessary for this decrease. Our
initial expectation was that TNF-RII engagement by itself
would not be sufficient to cause the observed decrease in
Bcl-2 levels. If it were, then the low (optimal) dose of anti-
gen, which stimulates both TNF-a and TNF-RII to maxi-
mal levels, would also be expected to decrease Bcl-2 levels
Figure 4. The apoptotic death
resulting from stimulation with
supraoptimal peptide–MHC de-
terminant density is mediated by
binding of TNF-a to TNF-RII.
To determine whether TNF-a
transduces the death signal via
TNF-RI or TNF-RII, CTLs
were stimulated with high (100
mM) or low (0.001 mM) con-
centrations of peptide in the
presence of blocking antibodies
to either TNF-RI or TNF-RII
(each at 5 mg/well). Proliferation
after stimulation with APCs
pulsed with high concentrations
of peptide antigen was restored
only in the presence of antibod-
ies to TNF-RII. The inability of the anti-TNF-RI antibody to prevent
death was not due to an inability to block signaling through this receptor
as this antibody could block TNF-a–mediated death in a TNF-a–sensi-
tive L929 cell line (data not shown).
Figure 5. TNF-a receptor regulation does not control the susceptibil-
ity to TNF-a–mediated apoptotic death. CTLs were analyzed for TNF-
RII expression and for the rate of proliferation after stimulation with sple-
nocytes pulsed with graded concentrations of I10 peptide. Concentrations
of peptide that induced maximal expression of TNF-RII did not correlate
with peptide concentrations required to induce death: both TNF-RII and
proliferation increased in parallel to reach maximums at similar peptide
concentrations. Thus, TNF-RII density was maximal at peptide concen-
trations insufficient to induce decreased proliferation (apoptosis) and re-
ceptor upregulation can not account for the switch to the TNF-a–sensi-
tive phenotype.1396 High Antigen Density Decreases Bcl-2 Levels In CTLs
and it does not. Nevertheless, to address this question, we
carried out two types of experiments (Fig. 7). First, we
asked whether the decrease in Bcl-2 levels seen with high
(supraoptimal) peptide stimulation in high avidity lines was
affected by blocking TNF-a signaling with anti–TNF-a.
As predicted by the ability of anti–TNF-a to prevent the
apoptosis of high avidity CTLs under these conditions,
anti–TNF-a also prevented the decrease in Bcl-2 levels in-
duced by high dose antigen (Fig. 7; compare the third and
fourth bars), demonstrating that TNF-a signaling was a
necessary requirement for the observed decrease in Bcl-2
levels. Second, we asked whether signaling by cross-linking
TNF-RII with antibody was sufficient to decrease Bcl-2.
To test this question, we first had to expose the high avid-
ity CTLs to low (optimal dose) antigen to upregulate
TNF-RII. 6 h after stimulation, we transferred the cells to
wells that were either untreated or coated with anti–TNF-
RII for a further 22–24 h. No decrease in Bcl-2 was ob-
served (Fig. 7; compare fifth and sixth bars). Thus, even
though TNF-a/TNF-RII signaling is necessary to induce
apoptosis, it is not by itself sufficient to cause either apopto-
sis or a decrease in Bcl-2 levels in the absence of a potenti-
ating signal engendered by the prior engagement of TCR
by high (supraoptimal) MHC–peptide.
The Apoptotic Death of High Avidity CTLs Induced by Su-
praoptimal Stimulation Is Caspase Dependent. Although the
role of caspases in Fas-mediated apoptotic death is well
documented (28–30), less is known about the involvement
of these proteases in the TNF-RII death pathway. To de-
termine the role of caspases in the apoptotic death resulting
from stimulation with supraoptimal peptide–MHC, we used
Boc-Asp-fluoromethyl ketone (BD-FMK), an irreversible
inhibitor of caspases. Recognition of the inhibitors by caspases
depends on the presence of an aspartic acid at the NH2 ter-
minus. ZFA-FMK, which lacks the target aspartic acid, was
used as a control. These cell permeant peptide-fluoromethyl
ketone caspase inhibitors have been previously shown to block
apoptotic death induced in T lymphocytes by a number of
stimuli (31). The presence of BD-FMK prevented the induc-
tion of apoptotic nuclear morphology in a dose titratable
fashion (Fig. 8), whereas the bZFA-FMK control inhibitor
had no effect. Thus the pathway used by the TNF-RII re-
ceptor when it signals death in CD81 T lymphocytes is
caspase dependent and shares a common pathway with other
death inducing receptors, e.g., Fas and TNF-RI (28–30).
Discussion
The results presented herein demonstrate that high avid-
ity CD81 CTLs can undergo apoptotic deletion as a result
Figure 6. The induction of apoptotic death is associated with a decrease in Bcl-2
levels. High and low avidity CTLs were cultured in the presence of immobilized
Dd (0.5 mg/well) pulsed with either 50 mM or 0.005 mM I10 peptide, or unpulsed.
After 24 h, CTLs were harvested and solubilized with 0.5% Triton X-100 lysis
buffer containing protease inhibitors. Lysates were analyzed by Western blot analy-
sis for expression of Bcl-2. Actin was used as a control to ensure equivalent loading
among the samples. High avidity CTLs stimulated with high peptide–MHC deter-
minant density have significantly decreased expression of Bcl-2 compared with CTLs stimulated with low peptide–MHC determinant density. Low avid-
ity CTLs stimulated with these same conditions showed no change in expression of Bcl-2. (A) Visualization of FITC-conjugated antibodies after transfer
of protein bands to nitrocellulose. In this experiment, Bcl-2 is not demonstrable in the high avidity CTL line after culture with high I10 peptide despite
a relatively higher amount of cell extract loaded on that lane (as assessed by the densities of the actin bands). (B) In a replicate experiment, binding of
FITC-conjugated antibodies was quantitated and the binding to Bcl-2 normalized by comparison with binding to actin. Quantitation in several experi-
ments showed that Bcl-2 in CTLs cultured with high peptide decreased to between 0 and 35% of the Bcl-2 present in controls. White bars, no peptide;
gray bars, 0.005 mM; black bars, 50 mM.
Figure 7. Signaling through
TNF-RII is not sufficient to de-
crease Bcl-2 levels, but TNF-a
signaling contributes to this ef-
fect. High avidity CTLs were
stimulated by transfer to soluble
Dd coated wells pulsed with op-
timal (0.0005 mM) or supraopti-
mal (50 mM) I10 peptide in ei-
ther the presence or absence of
anti–TNF-a. After 6 h, cells were transferred to either untreated wells or
wells coated with anti–TNF-RII and incubated for a further 22–24 h un-
der their initial media conditions. CTLs were then harvested and solubi-
lized with 0.5% Triton X-100 lysis buffer containing protease inhibitors.
Lysates were analyzed by Western blot analysis for determination of Bcl-2
concentrations. Actin was used as a control to ensure equivalent loading
among the samples. Anti–TNF-a blocked the decrease in Bcl-2 that oc-
curred after high avidity CTLs were stimulated with high peptide–MHC
determinant density. Substrate-bound anti–TNF-RII caused no decrease
in the levels of Bcl-2, either in the presence or in the absence of anti–
TNF-a, indicating that these conditions were not equivalent to stimula-
tion through the TCR by supraoptimal levels of peptide–MHC.1397 Alexander-Miller et al.
of supraoptimal peptide–MHC stimulation via secretion of
TNF-a and its subsequent binding to TNF-RII. The pre-
ponderance of literature reporting the induction of cell
death as a result of exposure to TNF-a suggests that the ap-
optotic signal is mediated by the TNF-RI receptor, which
contains a death domain similar to that in Fas (for review
see reference 32). However, TCR-induced apoptosis of
activated CD81 T cells appears different from the apoptosis
seen in other cell types in that it uses TNF-RII (8 and this
paper). Thus, TNF-RII may play a specialized role in this
subset of T cells. Furthermore, our results are the first to
demonstrate the caspase dependence of the TNF-RII sig-
naling pathway.
The death observed as a result of supraoptimal engage-
ment of the TCR on CTLs appears to result from a brief
initial encounter with antigen (Fig. 1). This suggests that
the signal generated is qualitatively different from that ob-
served when the same cell engages optimal antigen levels.
One major outcome of this different signal is that CTLs are
rendered susceptible to the apoptotic action of TNF-a.
During stimulation with optimal antigen concentrations,
CTLs produce both surface and secreted TNF-a and up-
regulate TNF-RII (Figs. 2, 3, and 5). This would suggest
that TNF-a should be able to signal through TNF-RII at
optimal antigen levels. However, under these circum-
stances either the TNF-a signal is ignored by the CTLs or,
alternatively, it may contribute to the activation of the
CTLs. Although TNF-RII lacks the death domain found
in TNF-RI and Fas, several “adapter” molecules have now
been identified that link TNF-RII with the Fas and TNF-RI
signaling pathways. TRAF (TNF receptor–associated fac-
tor) proteins associate with TNF-RII in the region that is
required for signal transduction (33). TRAF2 can interact
with TRADD, which has been shown to trigger apoptotic
death when over-expressed (13). Similarly, TRAF1 has
also been described as mediating apoptosis after cross-link-
ing of CD3 (34). Two additional proteins, IAP (inhibi-
tor of apoptosis)-1 and IAP-2, associate with TNF-RII
through their interaction with TRAF1 and TRAF2 and are
thought to be involved in signaling (33). Certainly the
pathway leading to death via TNF-RII signaling is com-
plex and the regulation of any one of a number of mole-
cules in the pathway may contribute to the differential sig-
nal resulting from high versus low dose stimulation.
The lack of correlation between apoptosis and the pro-
duction of TNF-a (secreted or surface) or of TNF-RII ex-
pression, despite the necessity of TNF-a/TNF-RII en-
gagement, is an intriguing issue. The fact that a TNF-a/
TNF-RII signal is necessary but not sufficient suggests that
alteration in levels of a third molecule must be postulated
to account for the observed apoptosis. The surprising in-
duction by high dose antigen of a decrease in Bcl-2 levels
may explain, in part, the increased susceptibility to death
after high dose antigen stimulation. Consistent with this in-
terpretation, in preliminary experiments we found that cells
exposed to high dose antigen, but prevented from under-
going TNF-a–mediated apoptotic death by addition of
anti–TNF-a, were more susceptible to other agents that
induced apoptosis, such as ionizing radiation (data not
shown). These observations are consistent with the accu-
mulation of a putative potentiating agent produced by
stimulation of the TCR with supraoptimal antigen. What-
ever this agent may be, it must act upstream of Bcl-2 regu-
lation, allowing Bcl-2 levels to be decreased in conjunction
with TNF-a/TNF-RII engagement.
Several studies have demonstrated the importance of Bcl-2
for the survival of lymphocytes (15, 35–37). Early studies
reported the ability of Bcl-2 to protect pre-B cell lines from
growth factor–induced apoptotic death (38). Furthermore,
in mice deficient in Bcl-2 T cells disappear from the pe-
riphery within the first 4 wk of life, suggesting a require-
ment for Bcl-2 in lymphocyte survival (35). In resting T cells,
Bcl-2 is expressed at low levels and is upregulated in re-
sponse to stimulation with mitogen or IL-2 (36). Using an-
tigen doses capable of inducing apoptotic deletion of CD81
cytotoxic T cells, we find that there is a specific reduction
in the level of Bcl-2, but little or no observable decrease in
Bcl-XL. This result is in agreement with a study using the
human T leukemia lines HL-60 and U937 (37) wherein
TNF-a–mediated death was correlated with downregula-
tion of the bcl-2 gene. We find that a decrease in Bcl-2 lev-
els depends on a supraoptimal antigen-induced signal
through the TCR, because the presence of TNF-a and its
receptor TNF-RII are not sufficient to induce this de-
crease, and direct cross-linking of TNF-RII with surface-
bound antibodies, even after stimulation with an optimal
dose of antigen, does not induce a decrease of Bcl-2 levels
(Fig. 7). Furthermore, the Bcl-2 decrease is prevented if
antibody to TNF-a is present during stimulation with supra-
optimal antigen, demonstrating that TNF-a signaling is
necessary, even though it is not sufficient. Thus Bcl-2 may
Figure 8. The apoptotic death of CTLs stimulated with high peptide–
MHC determinant density can be blocked by caspase inhibitors. High
avidity CTLs were stimulated with splenocytes either pulsed with 100 or
0.01 mM I10 peptide or unpulsed. BD-FMK or the control inhibitor
(bZFA-FMK) was added at the indicated concentrations. Apoptotic nu-
clear morphology was assessed by staining with Hoechst 33342. The pres-
ence of BD-FMK during stimulation of CTLs with supraoptimal concen-
trations of peptide greatly inhibited apoptotic death. No inhibition of
apoptotic nuclear morphology was observed with the control inhibitor,
bZFA-FMK, which lacks the target aspartic acid.1398 High Antigen Density Decreases Bcl-2 Levels In CTLs
be a major participant in the control of CTL survival dur-
ing the course of the immune response and may contribute
to the loss of CTLs observed when very high viral burdens
are attained, as is the case during infection with HIV.
Despite its direct correlation with apoptosis, the precise
mechanism controlling Bcl-2 levels is not clear. Clearly, all
three events, increase in surface and/or secreted TNF-a,
increase in surface TNF-RII, and decrease in Bcl-2, are
necessary in the course of high dose antigen induction of
apoptosis. However, both surface and secreted TNF-a and
TNF-RII increase to maximal levels at low antigen doses
that do not cause apoptosis. Of these three events, only the
decrease in Bcl-2 levels occurs solely at the higher antigen
doses that induce apoptosis. Thus, a high dose antigen sig-
nal through the TCR is necessary for induction of the Bcl-2
decrease, but a TNF-a signal is also necessary for the Bcl-2
decrease, as indicated by the ability to block with antibody
to TNF-a. Therefore, the situation is symmetrical in these
two requirements, as both are necessary and one cannot tell
which is potentiating for the other. We conclude that an
interaction of signals from the TCR and TNF-a leads to
the downregulation of Bcl-2 and thus to apoptosis. Future
studies will be needed to dissect the signal transduction
pathways from both these receptors to determine the intra-
cellular pathways involved. However, whatever the initiat-
ing signals, our study also demonstrates that the final path-
way for this TNF-a/TNF-RII–mediated death involves
caspases, as is already known for death through fas or TNF-
RI. Understanding this pathway will be important for de-
veloping ways to expand the repertoire of high avidity
CTLs without deleting them by inducing apoptosis, and to
preserve high avidity CTLs in the presence of high viral
burdens, since high avidity CTLs appear to be the key
CTLs necessary for control of viral infection (6, 39).
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